Ashfield Engage, part of UDG Healthcare plc., announced the completion of the acquisition of Nuvera LLC, a U.S.-based healthcare consulting firm specializing in patient support programs. Nuvera’s expertise in optimizing the design and build of seamless patient and HCP treatment experiences will enhance Ashfield Engage’s Patient Solutions capabilities and create an end-to-end strategic offering across their client’s product lifecycles.
As the U.S. moves from managing COVID-19 to managing a recovery, it is clear that the pandemic lockdowns had a profound impact on how people consume media, how they receive healthcare information, and their expectations changed around how brands connect with them. For marketers, building brand value with customers will be tantamount to marketing success in this brave new world.
As we continue to sift through the barrage of information regarding survival rates, resurgence, vaccines, and secondary illnesses, COVID-19 and its economic impact continues to be a primary global burden. In the midst of those serious concerns, the health and life sciences (HLS) industry continues its accelerated journey of perpetual assessment and evolution. As the industry emerges from the pandemic effect, leaders are realizing that COVID-19 has provided crucial learnings to their organizations that will benefit the entire industry, according to Astound Commerce’s Tina Wilson.
Rob Steere, VP commercial strategy (CRM) for Veeva Systems, discusses ways to maximize HCP engagement in a post-COVID world.
Patient communications are no longer fit for purpose, and although Covid has brought this to the fore, the problems will continue for a long time after the vaccine roll-out if they are not resolved.
The U.S. Food and Drug Administration approved GlaxoSmithKline plc’s Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.
PharmaLive talked to Conran Design Group Managing Director Christina Falzano about her experiences working with tech companies’ expansion into the health, wellness and pharma spaces in driving changes in the healthcare industry – especially in how they reposition post-COVID.
Pharmaceutical companies are no strangers to digital technology, either in the science that creates their products or in the business of bringing them to the people who prescribe them. As the use of digital-first experiences intensifies and the pharmaceutical industry is forced to evolve, companies will need to lean on their data and technologies in their engagement efforts to deliver elevated human experiences.
Greater Than One’s Christa Toole analyzes how healthcare marketers are adjusting to the current health crisis in a variety of ways.
The COVID-19 global pandemic, overcrowding of hospitals, the highly contagious virus affecting healthcare professionals and unrelated illnesses has led to a more than 1,000 percent increase of telemed application downloads and memberships. Is this a paradigm shift?